605 related articles for article (PubMed ID: 32037896)
1. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
2. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen.
Almeida H; Lobão P; Frigerio C; Fonseca J; Silva R; Sousa Lobo JM; Amaral MH
Pharm Dev Technol; 2017 May; 22(3):336-349. PubMed ID: 28240141
[TBL] [Abstract][Full Text] [Related]
4. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.
Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML
Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662
[TBL] [Abstract][Full Text] [Related]
5. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
7. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells.
Costa CP; Cunha S; Moreira JN; Silva R; Gil-Martins E; Silva V; Azevedo L; Peixoto AF; Sousa Lobo JM; Silva AC
Int J Pharm; 2021 Sep; 607():120933. PubMed ID: 34324988
[TBL] [Abstract][Full Text] [Related]
8. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
9. Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters.
Cunha S; Costa CP; Loureiro JA; Alves J; Peixoto AF; Forbes B; Sousa Lobo JM; Silva AC
Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32605177
[TBL] [Abstract][Full Text] [Related]
10. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
Salunkhe SS; Bhatia NM; Bhatia MS
Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
[TBL] [Abstract][Full Text] [Related]
11. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
12. New Thermoresponsive Eyedrop Formulation Containing Ibuprofen Loaded-Nanostructured Lipid Carriers (NLC): Development, Characterization and Biocompatibility Studies.
Almeida H; Lobão P; Frigerio C; Fonseca J; Silva R; Palmeira-de-Oliveira A; Lobo JM; Amaral MH
Curr Drug Deliv; 2016; 13(6):953-70. PubMed ID: 26502890
[TBL] [Abstract][Full Text] [Related]
13. Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers.
Yang CR; Zhao XL; Hu HY; Li KX; Sun X; Li L; Chen DW
Chem Pharm Bull (Tokyo); 2010 May; 58(5):656-61. PubMed ID: 20460792
[TBL] [Abstract][Full Text] [Related]
14. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
15. Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength.
Bagde A; Patel K; Kutlehria S; Chowdhury N; Singh M
Drug Deliv Transl Res; 2019 Aug; 9(4):816-827. PubMed ID: 30924025
[TBL] [Abstract][Full Text] [Related]
16. Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management.
Girotra P; Singh SK
AAPS PharmSciTech; 2017 Feb; 18(2):517-528. PubMed ID: 27126007
[TBL] [Abstract][Full Text] [Related]
17. Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design.
Kim MH; Kim KT; Sohn SY; Lee JY; Lee CH; Yang H; Lee BK; Lee KW; Kim DD
Int J Nanomedicine; 2019; 14():8509-8520. PubMed ID: 31749618
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery.
Varela-Fernández R; García-Otero X; Díaz-Tomé V; Regueiro U; López-López M; González-Barcia M; Isabel Lema M; Javier Otero-Espinar F
Eur J Pharm Biopharm; 2022 Mar; 172():144-156. PubMed ID: 35183717
[TBL] [Abstract][Full Text] [Related]
19. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
20. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]